Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07281417 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 90 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 14 → 18 locations Eligibility criteria expanded, about 32 words Show 1 more changeShow less
    • Eligibility criteria expanded, about 32 words
  2. Start date changed from estimate of Nov 24, 2026 to Sep 1, 2026v89
  3. Study sites: 13 to 14v88
  4. Study sites: 12 to 13v87
  5. Trial sites expanded: 8 → 12 locationsv86
Show 45 earlier versionsHide 45 earlier versions
  1. Study sites: 7 to 8v85
  2. Site details revised at 1 of 7 sitesv84
  3. Study sites: 5 to 7v83
  4. Study sites revised (5)v82 See this version in full on ClinicalTrials.gov ↗
  5. Study sites: 4 to 5v81
  6. Study sites: 5 to 4v80
  7. Site details revised at 2 of 5 sitesv79
  8. Study sites: 4 to 5v78
  9. Re-verified, no change to tracked fieldsv77
  10. Study sites: 2 to 4v76
  11. Study sites: 1 to 2v75
  12. Re-verified, no change to tracked fieldsv74
  13. Study sites: 2 to 1v73
  14. Study sites: 1 to 2v72
  15. 18 versions Re-verified since Mar 17, 2026, no change to tracked fieldsv54-v71
  16. Trial status: Not Yet Recruiting to Recruiting Primary and study completion dates: Oct 3, 2033 to Dec 16, 2030 · Start date: Feb 27, 2026 to Nov 24, 2026 · Study sites: 0 to 1v53 Show 3 more changesShow less
    • Primary and study completion dates: Oct 3, 2033 to Dec 16, 2030
    • Start date: Feb 27, 2026 to Nov 24, 2026
    • Study sites: 0 to 1
  17. 12 versions Re-verified since Feb 11, 2026, no change to tracked fieldsv41-v52
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial compares the effect of chemotherapy (carboplatin and paclitaxel) with versus without cemiplimab given before surgery (neoadjuvant) in patients with sinonasal squamous cell cancer. Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients with sinonasal squamous cell cancer is surgery followed by radiation therapy, with or without chemotherapy. Recently, some patients have also been treated with neoadjuvant chemotherapy before surgery. Adding cemiplimab to chemotherapy before surgery may be more effective at stopping the cancer from growing or spreading, compared to chemotherapy alone.
Trial Details
NCT Number NCT07281417
Lead Sponsor National Cancer Institute (NCI)
Conditions Sinonasal Squamous Cell Carcinoma, Stage III Sinonasal Cancer AJCC v8, Stage IVA Sinonasal Cancer AJCC v8, Stage IVB Sinonasal Cancer AJCC v8
Enrollment 108 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov